Category drugs

FDA delays decision on belimumab, and: on the reliability of clinical evidence

One day after my post on belimumab, the FDA announced it would be taking 3 more months to announce its decision on whether to approve it.  A news report cites that the agency wants more time to review the clinical data.  How does this shift the outcome for Benlysta?  It is uncertain.  The regulators could […]